Company intelligence / Profile preview

TWCC

Taipei City, Taiwantwcc.ai ↗

Ownership: Private
Development stage: Preclinical

Overview

TWi specializes in developing high-barrier generic drugs with technical complexity for the U.S. market. It also develops innovative therapies for rare diseases through its subsidiary TWi Biotechnology. The company has achieved several FDA approvals for generic products and advanced clinical programs targeting unmet needs such as epidermolysis bullosa simplex.

Therapeutic areas: ImmunologyDermatologyRheumatologyEndocrinology
Modalities: Small moleculesNovel drug delivery systems (nanoparticles, transdermal patches, polymeric oral delivery)
Industry: Biotech

Drug pipeline

1 asset

PLT012

Pre-clinical

Indications: liver cancer, colon cancer

Partnerships

Castle Creek Pharmaceuticals LLC — development/commercialization agreement for AC‑203 targeting epidermolysis bullosa simplex outside Asia/Australia/NZ region

Beyond the preview

Go deeper on TWCC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TWCC.

Explore the full profile